	US 11,970,544 B2
	Antibodies
David Satijn, Utrecht (NL); Esther C. W. Breij, Utrecht (NL); Bart E. C. G. De Goeij, Utrecht (NL); Kristel Kemper, Utrecht (NL); Patrick Engelberts, Copenhagen V (DK); Edward N. Van Den Brink, Halfweg (NL); Rik Rademaker, Utrecht (NL); Dennis Verzijl, Amstelveen (NL); Sjeng Horbach, Oss (NL); and Paul Parren, Odijk (NL)
Assigned to GENMAB A/S, Valby (DK)
Filed by GENMAB A/S, Valby (DK)
Filed on Jun. 21, 2021, as Appl. No. 17/353,087.
Application 17/353,087 is a division of application No. 16/813,167, filed on Mar. 9, 2020.
Application 16/813,167 is a continuation of application No. PCT/EP2019/056197, filed on Mar. 12, 2019.
Claims priority of application No. 18161293 (EP), filed on Mar. 12, 2018; and application No. 18175347 (EP), filed on May 31, 2018.
Prior Publication US 2022/0049013 A1, Feb. 17, 2022
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C12N 15/79 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/30 (2013.01) [A61P 35/00 (2018.01); C12N 15/79 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/565 (2013.01)]

31 Claims

1. A nucleic acid construct, or combination of nucleic acid constructs, encoding an antibody which binds to human 5T4 and comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 41, 42, and 43, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 45, the sequence DAS, and SEQ ID NO: 46, respectively.